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A collaborative work produced a new ADC linking together a 
potent and safe Histone Deacetylase inhibitor with a monoclonal 
antibody targeting the epidermal growth factor receptor. The 
targets of the HDAC inhibitor are epigenetically modulated 
inducing tumor cell death both in vitro and in vivo. The new ADC, 
delivered by aerosol, exhibits an outstanding therapeutic activity 
in a metastatic lung cancer model without apparent toxicity.
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We describe here two novel antibody-drug conjugates loaded with the HDAC inhibitor ST7612AA1 (IC50
equal to 0.07 mM on NCI-H460 cells), a thiol-based molecule with a moderate toxicity in vivo. Two
payloads were prepared using cleavable and non-cleavable linkers. After anchoring to cetuximab
through amide bond with lysines, the resulting HDAC inhibitor-antibody conjugates showed ability to
recognize EGFR and efficient internalization in tumor cells. Both ADCs induced sensible increment of
histones 3 and 4 and alpha-tubulin acetylation. Animal models of human solid tumors showed high anti-
tumor efficacy of the conjugates without the toxicity generally observed with traditional ADCs delivering
highly potent cytotoxic drugs. These compounds, the first ADCs charged with not highly cytotoxic
warheads, are potentially suitable for epigenetic modulation, extending the ADC strategy to the targeted
delivery of HDAC inhibitors with many possible therapeutic applications beyond cancer.Introduction
With more than 50 antibody-drug conjugates (ADC) in clinical
trials for treatment of oncological diseases, the ADC approach to
chemotherapy is nding renewed interest, especially aer Adcetris
(FDA, 2011), Kadcyla (FDA, 2013) and more recently Besponsa
(FDA, 2017) approval for treatment of CD30 +Hodgkin lymphoma,
Her-2-positive metastatic breast cancer and acute lymphoblastic
leukemia (ALL), respectively.1 While the use of monoclonal anti-
bodies (mAbs) and molecularly diverse linkers has been widely
represented, only highly potent cytotoxic drugs like microtubule
inhibitors maytansines (DM1/DM4) or auristatins (MMAE/MMAF)
dominate the current ADC landscape. Despite a relatively poor
clinical success rate, 70% of the ADCs currently in clinical trials
contains payloads belonging to these classes of molecules.2 Other
cytotoxic drugs include molecules targeting the DNA minor
groove,3,4 and topoisomerase I inhibitors.5 Since only <1% of the
injected dose is expected to target the tumor, the presence of
payloads active in nano- or picomolar ranges is thought to bearmacia, Universita` degli Studi di Siena,
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SI) available: Experimental procedures,
ra for characterisation. See DOI:a strict requirement for ADC-based therapies.6 Consequently,
most of the ADC toxicity observed in patients is deriving from off-
target effects due to linker instability. ADCs containing microtu-
bule inhibitors induce peripheral neuropathy, neutropenia,
gastrointestinal thrombocytopenia,7 hepatic and ocular toxicities8
while calicheamicin based ADCs cause thrombocytopenia and
hepatic dysfunction.9 With very few exceptions, until now the
paradigm that an efficient ADC must be charged with a highly
potent payload has guided ADC research and development.
However, the side effects associated with intrinsic cytotoxicity of
the payloads are a serious limit to the ADC applicability in ther-
apies beyond cancer.10 In addition, the potency of the cytotoxic
payload implies manufacturing problems in ADC production,
because of containment restrictions required to guarantee
protection of operators and environment.11 Compared to the
progress in development of ADCs in oncology, few ADC candi-
dates have been investigated for the treatment of other diseases.
Dexamethasone and budesonide have been linked to anti-CD70
antibodies for anti-inammatory and immunosuppressive thera-
pies.12 The highly cytotoxic Src kinase inhibitor dasatinib (IC50 < 1
nM) has been also linked to an antibody to produce an immu-
nosuppressive ADC.13 Finally, the recent discovery that a modied
rifampicin bonded to an anti-Streptococcus aureus antibody erad-
icates intracellular infection has raised great expectations for
ghting bacterial antibiotic resistance with ADCs.14
Epigenetic aberrations contribute to the onset and progres-
sion of several diseases via the gain or loss of function in
epigenetic regulatory proteins.15 Deacetylating enzymes are
valuable targets to treat aberrant deacetylations occurring inThis journal is © The Royal Society of Chemistry 2018
Scheme 1 Preparation of payloads/linkers for conjugation.
Edge Article Chemical Scienceneurological disorders, inammation, viral and protozoal
infections, cardiovascular disorders and cancer.16 We recently
discovered ST7612AA1 (ref. 17) (1, Scheme 1), a new thiol-based
histone deacetylase (HDAC) inhibitor that slows down in vivo
and in vitro growth of several tumors such as Ras-mutant colon
carcinoma, non-small cell lung tumors, ovarian cancer, triple-
negative breast cancer (TNBC), acute myeloid leukemia, and
diffuse large B cell lymphoma. Moreover, 1 showed to modulate
the NF-kB pathway and epithelial–mesenchymal transition
(EMT), as well as transcripts involved in immune response and
in key pathogenic pathways, suggesting the potential use in
management of inammatory diseases.18 Compound 1 also
proved to be active in HIV reactivation, with potential applica-
tions in therapies aiming at the eradication of the viral reser-
voirs.19 Compound 1 is the pro-drug of the corresponding thiol 2
(Scheme 1) that is rapidly formed in plasma aer the injection. A
high affinity of 2 with some histones isoforms (IC50 13, 5, 3 and
11 nM on HDAC-1, -3, -6 and -10 respectively) was observed
together with a promising activity of 1 on tumour cell lines (IC50
¼ 0.07 mM on NCI-H460 cells) and a moderate toxicity in vivo.17Results and discussion
Starting from this standpoint, we thought to exploit the features
of compound 1 into a new concept of ADC directed towardsThis journal is © The Royal Society of Chemistry 2018histone targets. The release of thiol 2 upon internalization of
a HDAC charged ADC, may open the way to selectively target
different HDAC isoforms with many potential applications in
cancer therapy and beyond, and other indications that might
possibly have benet from epigenetic modulations.
The clue of an effective ADC lies in its linker. Generally,
linkers are designed in such a way to discharge the drug
intracellularly through a controlled process. More stable linkers
can release the free toxin by unspecic endosomal degrada-
tion,2 while Cathepsin B cleavable linkers, discharge the
payloads upon lysosomal processing.20 As the active form of
ST7612AA1 (1) is a thiol (2), two alternative conjugation strate-
gies were exploited: (i) a linker based on the Michael addition of
the thiol to maleimide that might be cleaved by catabolism
(sharing features with the linker present in Kadcyla);21 (ii)
a cleavable linker based on the Val-Cit dipeptide22 bonded to
a p-amino-benzyl (PAB) self-immolative group.23,24 Both linkers
were attached through a stable amide bond with lysines to
cetuximab (Ctx), a monoclonal antibody (mAb) specic for the
Epidermal Growth Factor Receptor (EGFR). The linker-payloads
4 and 7 were thus prepared as described in Scheme 1. Aer
alkaline deacetylation of 1, Michael addition of thiol 2 to 3 gave
product 4 ready for lysine coupling aer N-hydroxysuccinimide
(NHS) in situ activation. Compound 7 was prepared starting
from dipeptide 5 aer deprotection and coupling with mono-
ethyl pimelate in the presence of EEDQ to give 6. The hydroxy
group was then transformed into the corresponding bromide
not stable enough for isolation. However, direct nucleophilic
substitution with thiol 2, followed by ester hydrolysis, gave acid
7 (Scheme 1). Compounds 4 and 7 were stable in PBS or in
mouse plasma. However, aer 5 h, hydrolysis of the ve-
membered ring of 4 started giving an almost complete trans-
formation into the monoamide of succinic acid in 12 h, as
revealed by NMR and MS/ESI (see ESI†).
This opened succinimide is stable in solution as no trace of
compound 2 was observed in the further 72 h.
This increased stability of ring opened succinimides have
been already documented in ADCs where maleimide was
employed for anchoring payloads to cysteines residues in the
mAb.25
Lysine anchoring was carried out with compounds 4 and 7
aer activation with NHS and incubation in DMSO/H2O/PBS
buffer (pH 7.4) with Ctx at room temperature using a 20
molar fold excess of the linker respect to the mAb (Scheme 2).
Purication of 8 and 9 was carried out by dialysis while
conjugation and DAR were determined by MALDI analysis that
showed DAR ¼ 8(1) for compound 8 and DAR ¼ 6(0.5) for
compound 9 (Fig. S1 and S2†). As expected, by HIC analysis the
conjugates 8 and 9 showed a large distribution of molecular
weights with less than 10% of unreacted antibody in any
sample. Size exclusion chromatography showed a major peak of
the size expected for conjugates 8 and 9 with minor peaks
referable to aggregated and degraded forms, respectively
(Fig. S3†).
The binding specicity of conjugates 8 and 9 was than
conrmed by ow-cytometry (FACS analysis) on Capan-1
(human pancreas carcinoma), NCI-H1975, A549 (human lungChem. Sci., 2018, 9, 6490–6496 | 6491
Scheme 2 Preparation of ADCs 8: DAR ¼ 8 (1), average on 6
batches; and ADC 9: DAR ¼ 6 (0.5), average on 3 batches.
Fig. 2 Effect of native Ctx (lane 2), ADCs 8 or 9 (lanes 3 and 4,
respectively) on acetylation of alpha-tubulin and histone H4 in A549
(human lung carcinoma) cells. Cells were cultivated 3 hours at 37 C
with medium (lane 1) or antibodies (20 mg mL1) and then western blot
analysis was carried out on total protein lysates. Beta-actin was used
for normalization. One representative blot is shown.
Chemical Science Edge Articlecarcinoma), and SK-MEL-28 (human melanoma) cell lines,
a panel of EGFR positive and negative tumour cells (Fig. S4†).
Immunoreactivity was tested by antigen-specic ELISA on a 96-
well plate coated with 50 ng per well of recombinant human
EGF-R/ErbB1 Fc chimera. Both ADCs showed reactivity with
their specic target with potency comparable (ADC 8) or slightly
but signicantly lower (ADC 9) to that of Ctx (Fig. S5a†).
Consistently, affinity measurements by surface plasmon reso-
nance (Biacore system) showed an apparent higher affinity of 8
compared to 9 although both derivatives exhibit antigen inter-
action kinetics in the same sub-nanomolar range of Ctx
(Fig. S5b†).
Aer securing that conjugation did not modify the Ctx
properties, ADC internalization, an essential step for biological
function, was investigated on the EGFR-expressing tumour cell
lines Capan-1, NCI-H1975, A549 (Fig. 1a), and on EGFR-negative
cells (Fig. S6b†). Aer cell treatment with Alexa Fluor488-
labeled ADCs, uorescence was observed by High Content
Screening (HCS) imaging analysis. Results show that, upon
binding to EGFR, ADCs 8 and 9 are internalized in a comparable
manner respect to Ctx, resulting in accumulation within the
internal vesicles of the multivesicular bodies and subsequent
translocation to the lysosomal compartment (Fig. 1a).
To demonstrate that the HDAC inhibitor charged ADCs 8
and 9 are suitable for epigenetic modulation, the release of 2Fig. 1 (a) Internalization of Ctx and ADCs 8 and 9 in Capan-1 (pancreas c
their effect on acetylation of HDAC-target proteins in NCI-H1975 cells. I
representative of at least 5 fields of duplicate wells. Magnification 60. D
6492 | Chem. Sci., 2018, 9, 6490–6496was then proven in NCI-H1975 cells by detecting acetylation of
alpha-tubulin and histones, a clear mark of specic inhibition
of HDAC6 and nuclear HDAC isoforms,26 respectively (Fig. 1b).
Fluorescence data showed that all tested ADCs induced a rele-
vant increase in the acetylation level of both alpha-tubulin and
histones H3 and H4, as result of direct enzymatic inhibition of
HDAC6 and class I HDACs, respectively while no effect was
observed in cells treated with Ctx alone (Fig. 1b), in EGFR-
negative cells and in other cell lines assessed (Fig. S7 and
S8†). Increased acetylation of tubulin and histone H4 was also
conrmed in A549 cells by western blot analysis of total protein
lysate (Fig. 2). Comparison of band intensity clearly shows an
increment of acetylation when cells are treated with ADCs 8 and
9 if compared with the vehicle-treated cells and with cells
treated with Ctx.
This result demonstrates the ability of ADCs to be internal-
ized and to acts as a HDAC inhibitor, due to the presence of
compound 2 indeed.27
Release of 2 from ADC 8 occurred by treatment with human
hepatic microsomes.28 Aer 72 h of incubation at 37 C, quan-
titative HRMS analysis showed the presence of the peaks at m/z
¼ 362.1548 and 328.1671 referable exclusively to compound 2 in
concentration 1.9 mM (29% of release referred to the amount of
payload present in the starting ADC.) When ADC 9 was
submitted to the same procedure, with evidence of 2 was found.arcinoma), A549 and NCI-H1975 (lung carcinoma) human cells, and (b)
nsets show specific fluorescence signals within the cells. Each image is
ata are from one representative experiment out of two.
This journal is © The Royal Society of Chemistry 2018
Edge Article Chemical ScienceThe linker Val-Cit-PAB conjugated with 2 is known to be cleaved
by lysosomal Cathepsin B.
However, in our hands, different incubation experiments
carried out on compound 7 or ADC 9 with the isolate enzyme or
hepatic microsomes, never gave convincing proofs of the pres-
ence of 2 or, at least, of the PAB-thioether derived from 2 by
amide cleavage. Cellular metabolism might generate the drug
attached to amino acid fragments derived from the antibody29–31
and, successively, 2. Submitting the structure 7 to MetaSite,
a soware that predicts metabolic transformations related to
cytochrome and monooxygenase mediated reactions,32 2 is
revealed as a possible metabolite (ESI†). This putative metabolic
mediated release of 2 from ADC 9 may explain why this ADC is
only slightly more therapeutically potent than Ctx alone sug-
gesting also that the linkage through Val-Cit PAB was not a good
choice for a correct release.Fig. 3 (a) Effects of ADC 8 and 9 in tumours developed in Nu/Nu mice a
response to antibody treatment wasmonitored using a Vernier calliper. M
days) or 1 (4 doses of 120 mg kg1 once every 4 days) and PBS (n ¼ 8 m
Mann–Whitney's test). (b) Effects of ADC 8 in tumours developed in Nu
development and response to antibody treatment was monitored using
50mg kg1 once every 4 days) or PBS (n¼ 10mice/group; mean and SEM
test. (c) Artificial metastatic lung cancer experiment carried out with 5 
SCID/beige mice. Tumour bioluminescence imaging (BLI) was recorded b
and +56 days from cell injection), after i.p. injection of luciferin (150 mg per
of 100 mgmL1 solution) q7dx4 (n¼ 12 mice/group; mean and SEM, p <
tumour pancreas experiment performed with 1  106 tumor Capan-1 c
tumor injection. Mice treated intraperitoneally with 8 or Ctx (4 doses of 4
mice/group); mean and SEM, p < 0.05 vs. Ctx,*p < 0.05 and **p < 0.01
This journal is © The Royal Society of Chemistry 2018However, the activity of ADC in epigenetic modulation can be
explained exclusively assuming that 2 is released. The largely
accepted pharmacophore model for most of the known
hydroxamic acid inhibitors consists of (a) a capping group that
interacts with the residues at the active site entrance (cap), (b)
a zinc binding group (ZBG) that coordinates to the catalytic
metal atom within the active site, and (c) a linker that binds to
the hydrophobic channel and helps Cap and ZBG to nd the
correct position.33 The accommodation of the ZBG into the
HDAC catalytic site is a crucial step of the inhibition process
and is nely controlled by its zinc coordination ability and by
key interactions with the surrounding protein residues. More-
over, the distance between the ZBG and the cap must be
between 6.6 and 7.2 A˚ in order to have molecules with activity as
HDAC inhibitors.34,35 These molecular features do not t with
amino acid conjugate coming from a partial metabolism of
ADC 9.fter s.c. injection of 5  106 NCI-H1975 cells. Lesion development and
ice injected i.p. with either 8, 9, Ctx (4 doses of 50mg kg1 once every 4
ice/group; mean and SEM, p < 0.001 and p < 0.01 vs. Ctx alone,
/Nu mice for 13 days after s.c. injection of 5  106 A549 cells. Lesion
a Vernier calliper. Mice injected i.p. with either 8 and Ctx (4 doses of
, p < 0.05 vs.Ctx; **p < 0.01 and *p < 0.05 vs. vehicle, Mann–Whitney's
106 A549-luc-C8 (A549luc) cells into the tail vein of immunodeficient
y Xenogen IVIS Imaging System 200, at different time points (+35, +49
mouse). Mice were treated by aerosol with PBS or ADC 8 or Ctx (3.5mL
0.01 vs. cetuximab; *p < 0.05 and **p < 0.01 vs. vehicle). (d) Orthotopic
ells injected into pancreas. Tumor weight was evaluated 90 days after
0 mg kg1 once every 4 days), PBS and 1 (200 mg kg1, q4dx4) (n ¼ 10
vs. vehicle).
Chem. Sci., 2018, 9, 6490–6496 | 6493
Chemical Science Edge ArticleThe putative anti-proliferative activity of conjugates was
evaluated on two lung adenocarcinoma cell lines (NCI-H1975
and Calu-3), treated up to 6 days with ADC 8 or ADC 9, as well
as with equivalent doses of the parental antibody (free Ctx). As
determined by cell proliferation curves, although at different
extent ADC 8 inhibited tumour cell proliferation of both cell
lines, showing IC50 value of 250 nM on NCI-H1975 cells and
40% of inhibition at the highest measured dose (500 nM) on
Calu-3 cells. Although not extremely potent, conjugates 8 and 9
resulted much more active than Ctx alone that, at the same
concentration, was not effective (Fig. S9†).
However, ADC 8 and 9 showed a high antitumor activity in
animal models (Fig. 3). Their efficacy in comparison with Ctx and
1 was evaluated in a mouse tumour xenogra model (non-small
cell lung). The NCI-H1975 tumour cells were injected subcuta-
neously into nude Nu/Nu mice (day zero). By day 11, treatment
was initiated when tumour lesions reached 100 mm3. Mice
were randomized and injected with vehicle (PBS), 8, 9, 1 and Ctx
(Fig. 3a). Mice treated with 8 showed absence of tumour in 50%
of mice up to 90 days aer the tumour injection. Although at
a lower extent, also ADC 9 exhibited an anti-tumour activity,
signicantly higher than Ctx. No activity was observed with PBS
or 1, although the latter was used at high dose.18 Based on this
result, ADC 8 was investigated in additional tumour models. In
A549 NSCLC injected in nude Nu/Nu mice, the compound
showed signicant antitumor activity compared with Ctx
(Fig. 3b). We were also delighted to observe that ADC 8 proved to
be effective in a severe metastatic lung cancer model done by
injecting type A549-luc-C8 (A549luc) cells into the tail vein of
immunodecient SCID/beige mice. Aer 1 week from tumour
injection, animals were treated with ADC 8 or unconjugated Ctx
by whole body aerosol (Fig. 3c). The evaluation of biolumines-
cence, analysed at three different times (35-49-56 days), showed
that ADC 8 signicantly inhibits tumourmetastases with a higher
potency in comparison with Ctx alone (Fig. 3c). Comparison
among ADC 8, 1 and Ctx was nally evaluated in a mouse model
of the highly aggressive CAPAN-1 orthotopic pancreatic tumour.
Treatments with ADC 8, 1 and Ctx started 6 days aer tumour
inoculation and, 90 days aer tumour injection, mice were
sacriced to analyse the pancreas tumour weight. ADC 8 showed
to inhibit the tumour growth of 84% with 6 complete responsesFig. 4 Body weight of NCI-H1975 tumor bearing mice, throughout
the experiment described in Fig. 2a.
6494 | Chem. Sci., 2018, 9, 6490–6496(6 pancreas free from tumour), while Ctx gave 50% of tumour
growth inhibition with 2 complete responses.
Compound 1 alone showed a lower activity on tumour
growth (38%) although with ve complete responses (Fig. 3d).
Finally, it is worth noting that compound 8 showed the same
toxicity than Ctx alone (Fig. 4). The body weight of mice treated
with 8 was not affected throughout all the study duration,
indicating that the treatment is well tolerated (Fig. 4).
In vivo combination study with Ctx and ST7612AA1 alone,
demonstrated also that an equimolar mixture of the uncoupled
drug and the antibody was well tolerated but not effective in the
animal model. Overall, in vitro and in vivo results show that ADC
8 is a promising lead for further therapeutic applications and
that its high activity is clearly due to conjugation of the HDAC
inhibitor to the antibody.Conclusions
In conclusion, we have developed a new class of ADCs charged
with HDAC inhibitors. Conjugates 8 (ST8154AA1) and 9
(ST8155AA1), the rst example of an ADC for epigenetic modu-
lation, delivered the HDAC inhibition to cells expressing the
antibody antigens, inducing signicant increment of histones 3
and 4 and a-tubulin acetylation. Animal models of human solid
tumours indicate anti-tumour efficacy of such conjugates without
the toxicity generally observed with traditional ADCs charged
highly potent cytotoxic drugs. Overall, comparison of data
suggests that ADC 8 is superior to 9, probably due to the inuence
of the linker design and the release processes. With the prepa-
ration of ADCs 8 and 9 we have disclosed that it is possible to
obtain active ADCs even with not highly cytotoxic warheads, with
exceptional potential of decreasing the side effects of this class of
drugs. This work clearly demonstrates that the paradigm ADC-
cytotoxic payload can be overcome with many advantages for
applications of ADCs beyond cancer therapy. Further work is in
progress to understand why HDAC inhibitor payloads are
different from numerous other tested in ADC eld and to
ascertain if the possibility to successfully conjugate medium/low
cytotoxic drugs is limited to HDAC inhibitors or may be extended
to other biologically active compounds.Live subject statement
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